Anticoagulant activity of apixaban can be estimated by multiple regression analysis
| Autor: | Yuya Ise, Naoko Unami, Hidenori Suzuki |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
lcsh:Diseases of the circulatory (Cardiovascular) system anticoagulants DOAC apixaban 030204 cardiovascular system & hematology Gastroenterology Anticoagulant activity 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine medicine atrial fibrillation 030212 general & internal medicine Prothrombin time Creatinine medicine.diagnostic_test business.industry Warfarin Atrial fibrillation Regression analysis Original Articles medicine.disease Thrombosis prothrombin time chemistry lcsh:RC666-701 Apixaban Original Article Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Journal of Arrhythmia Journal of Arrhythmia, Vol 36, Iss 6, Pp 1032-1038 (2020) |
| ISSN: | 1883-2148 1880-4276 |
| Popis: | Background Information on apixaban anticoagulant activity is required to prevent major bleeding or thrombosis during its use. Methods We enrolled 194 patients with nonvalvular atrial fibrillation (NVAF) in whom warfarin was replaced with apixaban: 105 (54.1%) received the standard dose of apixaban (5 mg twice daily [BID]; 5 mg group) and 89 (45.9%) received a reduced dose (2.5 mg BID; 2.5 mg group). Multiple regression analysis was performed to predict the prothrombin time of apixaban (PTa) based on factors including age, body weight (BW), serum creatinine, and CHA2DS2‐VASc score. Results PTa and PT of warfarin (PTw) were significantly correlated in both groups (correlation coefficient R = 0.239 [P = .014] in the 5 mg group; R = 0.248 [P = .019] in the 2.5 mg group). PTa in the 5 mg group was predicted as follows: 16.952‐0.036 × BW +0.299 × CHA2DS2‐VASc score (P Estimation of anticoagulant activity of apixaban. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text